Q-omics provides the consensus-scored NDUFB10 profile across patient tissues and cancer cell-line models. NDUFB10 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in UCS. Among the 18 cancer types available for tumor–normal comparison, NDUFB10 is differentially expressed in 8, with the highest sampling consensus in KIRC. Additionally, NDUFB10 protein abundance shows 23,135 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight UCS, KIRC, and GBM as cancer lineages where NDUFB10 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for NDUFB10 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes NDUFB10 survival associations across molecular data types. NDUFB10 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (2) and mass-spec protein abundance (8). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible NDUFB10 RNA expression–survival associations across cancer types. High NDUFB10 expression shows unfavorable associations in UCS, UVM, SCLC, LAML and ESCA, but favorable associations in KIRP. The UCS Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UCS as the clearest survival context for NDUFB10 RNA expression.
This table summarizes NDUFB10 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8, while mass-spec protein shows differences in 6. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for NDUFB10. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. NDUFB10 shows higher tumor expression in KIRC, LIHC, KIRP, BRCA, LUSC and LUAD. The KIRC box plot shows higher NDUFB10 RNA expression in tumor versus normal tissue (log2 FC = +0.315, t-test p < 0.001).
This table shows molecular features associated with NDUFB10 in patient tissues and cancer cell lines. In patient samples, NDUFB10 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, NDUFB10 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LIVER, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and BREAST.
